BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 29, 2020 5:00 PM
Oral Presentation:
Title: | |
Abstract #: | 8007 |
Session Title: | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
Lead Author: | |
Poster Presentations:
Title: | Three-Year Follow-up of Treatment-Naïve and Previously Treated Patients with Waldenström Macroglobulinemia (WM) Receiving Single-Agent Zanubrutinib |
Abstract #: | 8051 |
Poster #: | 384 |
Session Title: | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
Lead Author: | |
Title: | Phase 3 Study of Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First line (1L) Treatment for Advanced Squamous Non-Small Cell |
Abstract #: | 9554 |
Poster #: | 320 |
Session Title: | Lung Cancer—Non-Small Cell Metastatic Poster Session |
Lead Author: | |
Title: | Association Between Immune and Tumor Gene Signatures with Response or Resistance to Tislelizumab Monotherapy or in Combination with Chemotherapy in Gastroesophageal Adenocarcinoma |
Abstract #: | 3115 |
Poster #: | 179 |
Session Title: | Developmental Therapeutics—Immunotherapy Poster Session |
Lead Author | |
About
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 3,500+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market two internally-discovered oncology products: BTK inhibitor BRUKINSA™ (zanubrutinib) in the
BeiGene Investor Contact | BeiGene Media Contact |
+1 857-302-5189 ir@beigene.com | +1 857-302-5663 media@beigene.com |